001367: Zhejiang Haisen Pharmaceutical Co., Ltd. - Summary | Jitta

Zhejiang Haisen Pharmaceutical Co., Ltd.

CHN:001367

Price
CN¥16.40
Loss Chance
42.5%
6.59JITTA SCORE
23.93%Over Jitta Line
Jitta Ranking
18 / 489
199 / 5,285
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (67)
Recent Business Performance (97)
Financial Strength (90)
Return to Shareholders (20)
Competitive Advantage (55)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Operating MarginConsistent
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
Recent IPOLess than 3 years
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
6.59
23.93%
4.35
810.56%
4.24
> 1,000%
Pharmaceuticals
7.37
16.73%
5.11
54.91%
7.72
15.60%
COMPANY DESCRIPTION
Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers, and digestive and cardiovascular applications. It also provides chemical products for use as paroxetine HCl and amikacin sulphate intermediates and food additives; and escitalopram oxalate tablets to treat depression and panic disorders under the Tezi brand. In addition, the company engages in the import and export of goods; trading; and medical research and experimental development activities. Zhejiang Haisen Pharmaceutical Co., Ltd. was incorporated in 1998 and is headquartered in Dongyang, China.